Respibron

General characteristics. Structure:

1 tablet of drug Respibron contains:
 The bacterial lysate which is dried up from the frozen state – 50 mg;
 Additional ingredients.
 
7 mg of a bacterial lysate correspond:
 Streptococcus viridans – 6х109 units;
 Streptococcus pyogenes – 6х109 units;
 Staphylococcus aureus - 6х109 units;
 Klebsiella ozaenae – 6х109 units;
 Klebsiella pneumoniae – 6х109 units;
 Neisseria catarrhalis – 6х109 units;
 Haemophilus influenzae B – 6х109 units;
 Diplococcus pneumoniae – 6х109 units (in particular on 1х109 units of such types: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).

Pharmacological properties:

Respibron – the immunomodulatory drug containing a bacterial lysate. Respibron promotes increase in a specific immune response due to increase in level of serumal and secretory antibodies, and also activation of mechanisms of humoral and cellular nonspecific immunity.
Respibron promotes reduction of frequency of development of infectious respiratory diseases, and also decrease in weight of a course of infectious diseases of respiratory tracts. Drug use Respibron as preventive and remedy allows to reduce the need for an antibioticotherapia.
The technology of receiving native high-immunogene material from large fragments of cell walls of microorganisms allows to stimulate the high level of products of specific antibodies.
 
Respibron activates a nonspecific immune response due to activation of dendritic cells, macrophages, neutrophils and Nk-cells, and also induction of a cellular lysis and phagocytosis owing to increase in adhesion of macrophages on bacteria.
еспиброн activates a specific immune response due to stimulation of products interleykina-2, activation of effector SD4 and SD8 T - and V-lymphocytes, and also increase in products of specific serumal immunoglobulins A, M, G and sIgA.
 Tablets Respibron promote increase in products interleykina-2, interleykina-12, interleykina-10, Ifhg (CD4+ Th of type 1), and also to increase in an expression of a receptor to CD4+ and CD8 + in T lymphocytes, SILT-2 in V-lymphocytes, quantities of CD4+ and CD8 + effector T-cells of in vitro.
 
In vivo at drug use Respibron is noted increase in activity of immunoglobulin M of V-lymphocytes of memory (CD27+, CD24+), receptor expression to CD4+ and CD8 + in T lymphocytes and SILT-2 in V-lymphocytes, amounts of secretory immunoglobulin A on mucous membranes of bodies of respiratory system.
At sublingual use drug Respibron is well absorbed in a system blood stream.

Indications to use:

Respibron is intended for therapy of the patients suffering from acute and subacute forms of infectious diseases of upper respiratory tracts of various etiology. Tablets Respibron can be applied as prophylactic at patients with chronic and recurrent infectious diseases of upper respiratory tracts of various etiology.
In particular Respibron appoint to patients with acute respiratory viral infections, flu, bacterial tonsillitis, pharyngitis, laryngitis, sinusitis, epiglogity and quinsy, and also bacterial, viral and allergic rhinitis.
Besides, Respibron can be appointed as medical and prophylactic at various forms (chronic, acute, subacute and recurrent) infectious diseases of the lower respiratory tracts. Including sublingual tablets are appointed to patients with tracheitis, bronchitis, a tracheobronchitis, bronchiectasias, chronic diseases of lungs with the obstruction phenomena.
 
Respibron is recommended as prophylactic to children with frequent acute respiratory diseases and chronic obstructive diseases of lungs.
Sublingual tablets Respibron apply in complex therapy of the infections caused by microorganisms, resistant to an antibioticotherapia and also the complications which developed against the background of bacterial or viral infectious diseases.

- Acute, subacute, recurrent and persistent infections of upper respiratory tracts (rhinitis, sinusitis, laryngitis, pharyngitis)
- Acute, subacute, recurrent and persistent infections of the lower respiratory tracts (tracheitis, bronchitis, bronchiectasias)
- Thanks to the immunomodulatory action Respibron reduces quantity and intensity of cases and has preventive effect concerning a recurrence.

Route of administration and doses:

Respibron is intended for sublingual use. The tablet is recommended to be held in an oral cavity before full dissolution. Children, for convenience of administration of drug, are allowed to crush a tablet and to dissolve in a small amount of drinking water (near 10-15ml). For achievement of the maximum pharmacological effect it is not necessary to eat food within 30 minutes after administration of drug Respibron. Respibron determines duration of use and the scheme of administration of drug the doctor.
To patients with acute diseases, as a rule, appoint on 1 sublingual tablet a day. The minimum recommended course of treatment makes 10 days. Respibron it is necessary to accept before total disappearance of symptoms of a disease (administration of drug is possible more than 10 days in a row only under careful control of the attending physician).

As prophylactic Respibron, as a rule, appoint on 1 tablet a day. Duration of reception makes 10 days. 20 days later it is recommended to repeat a course of administration of drug. The general course preventive dose of drug Respibron makes 30 tablets (3 courses of reception for 10 days with an interval of 20 days).

Side effects:

Respibron, as a rule, is not bad had by patients. It was reported about isolated cases of development of allergic reactions during therapy by drug Respibron. In case of hypersensitivity reaction development reception of tablets Respibron should be stopped.

Interaction with other medicines:

Without features.

Contraindications:

Respibron patients should not appoint with individual intolerance of ingredients of drug.
Respibron is not recommended to apply to treatment of children is younger than 2 years.

Pregnancy:
Respibron it is not necessary to apply to therapy of women in the first trimester of pregnancy. Before an initiation of treatment drug Respibron at women of childbearing age it is necessary to exclude pregnancy. When planning pregnancy it is not necessary to use drug Respibron. In the second and third trimester Respibron makes the decision on drug use the doctor, considering possible risks for a fruit.
In the period of a lactation sublingual tablets Respibron are appointed with care after the solution of a question of possible interruption of breastfeeding.

Overdose:

Now messages on drug overdose Respibron did not arrive.

Storage conditions:

Respibron it is necessary to store no more than 3 years after production in rooms with a temperature which is not exceeding 25 degrees Celsius.

Issue conditions:

According to the recipe

Packaging:

Sublingual tablets Respibron in blister strip packagings on 10 pieces, 1 or 3 blisters are enclosed in a cardboard pack.